Silexion Therapeutics climbs on promising cancer drug data

Silexion Therapeutics

30/09/2025 13:59

** Shares of drug developer Silexion Therapeutics SLXN.O rise 11% to $3.75 premarket

** Says its experimental cancer drug, SIL204, showed strong activity in lab tests, targeting a wide range of KRAS mutations linked to aggressive cancers

** Reports inhibition rates between 83.5% and 99.7% in 11 human cancer cell lines, including its first data in gastric cancer and expanded results in colorectal cancer

** SIL204 also showed high potency against the G12R mutation, which affects about 17% of pancreatic cancer patients

** Plans to start mid-to-late stage trials in the first half of 2026

** As of last close, stock down 88% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))